Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.44
+0.06004.35%
Post-market: 1.440.00000.00%18:36 EDT
Volume:3.59M
Turnover:5.00M
Market Cap:312.86M
PE:-1.09
High:1.46
Open:1.33
Low:1.32
Close:1.38
Loading ...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

GlobeNewswire
·
28 Mar

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Mar

Allogene Therapeutics Price Target Maintained With a $10.00/Share by RBC Capital

Dow Jones
·
14 Mar

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Zacks
·
14 Mar

RBC Capital Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Mar

TD Cowen Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Mar

Allogene Therapeutics Inc Q4 Loss Per Share $0.28

Reuters
·
14 Mar

Allogene Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Mar

Allogene Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
14 Mar

Allogene Therapeutics Inc - Q4 Shr Loss $0.28

THOMSON REUTERS
·
14 Mar

Allogene Therapeutics Q4 EPS $(0.28) Beats $(0.33) Estimate

Benzinga
·
14 Mar

Allogene to invest $37.3M in expanded MRD assay pact with Foresight Diagnostics

TIPRANKS
·
26 Feb

Allogene Therapeutics Inc - Expanded Collaboration to Develop Mrd Assay in EU, UK, Canada, Australia

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc - on Feb 19. Amended Strategic Collaboration Agreement With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Inc: Expands Strategic Partnership With Foresight Diagnostics

THOMSON REUTERS
·
26 Feb

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

GlobeNewswire
·
26 Feb

Baird ‘encouraged’ by Allogene CAR-T therapy update

TIPRANKS
·
19 Feb

Allogene Therapeutics Up Nearly 42%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
15 Feb

William Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 Feb

BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

Reuters
·
14 Feb